| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.09 | 0.1 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.1 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.1 |
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | leptomycin B | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | RDEA119 | FIMM | pan-cancer | AAC | 0.34 | 0.1 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.057 | 0.1 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.089 | 0.1 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.2 | 0.1 |